Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain (DEIS)

Grupo Español Multidisciplinar de Melanoma

Status: Completed

Conditions: Malignant Melanoma Stage IIIc; Malignant Melanoma Stage IV

Treatments: Drug: Trametinib

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT02439411

GEM1401

Details and patient eligibility

About

The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.

Enrollment: 135 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have received at least one dose of dabrafenib or combination with trametinib as part of a compassionate use for the treatment of metastatic melanoma, with deadline the start of treatment the April 30, 2014.

Exclusion criteria

• Patients with a history not available.

Trial design

135 participants in 2 patient groups

Dabrafenib

Dabrafenib plus Trametinib

Description:

Patients treated with Dabrafenib plus Trametinib

Treatment:

Drug: Trametinib